U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466940) titled 'A Clinical Study to Evaluate SM17 in Healthy Participants' on March 03.
Brief Summary: This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants. It also aims to evaluate the bioavailability of SM17 SC compared to SM17 IV.
Study Start Date: Oct. 14, 2025
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Asthma
Inflammatory Bowel Disease
Intervention:
BIOLOGICAL: SM17
SM17 monoclonal antibody
DRUG: SM17 placebo
placebo to be compared with SM17, excipient solution ...